The scientific focus adapted
to express the optimum potential
of your molecule

Unparalleled vision in metabolic disorders and risk assessment expertise for post-marketing studies and drug repositioning.

HeartArteryMacrophageLiverMusclePancreasAdipose Tissue

Preclinical development:
In-house predictive models and tracer technologies enable the generation of Proof of Concept efficacy data for your drugs.

Screening and lead validation utilize a dedicated research platform which combine with our focused scientific vision.

Home > News > 55th EASD Annual Meeting in Barcelona, Spain.

News detail

Return to all news & events

09/10/2019 55th EASD Annual Meeting in Barcelona, Spain.

EASD Annual Meeting 2019

Physiogenex will attend the 55th EASD Annual Meeting on September 17, 2019 in Barcelona.

Dr. François Briand, our Director of Research and Business Development, will present a poster during the Posters Sessions PS 037 (Diet, bugs and drugs) on Tuesday September 17, 2019 from 12pm to 1pm.

Poster: “Liraglutide shows better weight-loss and cardiometabolic benefits than lorcaserin and pioglitazone in a novel diet-induced obese rat model.”

Dr. Briand will be happy to discuss with you about your drug development projects.

Please Contact us if you wish to set up an appointment.

About us

Physiogenex is a leading preclinical contract research organization providing non clinical services in metabolic disorders and complications.

We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We have a strong expertise on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.